Why we should be vigilant: Drug cytotoxicity observed with in vitro transporter inhibition studies

Biochemical Pharmacology

Volumn 80, Issue 7, 2010, Pages 1087-1092

  Zheng, Xiaowan ^a   Diao, Lei ^a   Ekins, Sean ^a,b,c   Polli, James E ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Collaborations in Chemistry ^*  (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cytotoxicity; HEK cells; Inhibition; MDCK cells; Transporter

Indexed keywords

AMLODIPINE; APICAL SODIUM DEPENDENT BILE ACID TRANSPORTER; CARRIER PROTEIN; CARVEDILOL; CHLORPHENIRAMINE; CLOZAPINE; DESLORATADINE; DILTIAZEM; EXCITATORY AMINO ACID TRANSPORTER 4; FLUINDOSTATIN; IMATINIB; IMIPRAMINE; INDOMETACIN; LANSOPRAZOLE; LATANOPROST; MEVINOLIN; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; ORGANIC CATION CARNITINE TRANSPORTER 2; OUABAIN; PROPAFENONE; SIMVASTATIN; THIORIDAZINE; TIOCONAZOLE; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE; COTRANSPORTER; ORGANIC ANION TRANSPORTER; SODIUM-BILE ACID COTRANSPORTER;

ARTICLE; CELL LINE; CELL STRAIN; COMPETITIVE INHIBITION; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; ENZYME SUBSTRATE; IN VITRO STUDY; PHARMACOPHORE; PRIORITY JOURNAL; HUMAN; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL; WAKEFULNESS;

BIOLOGICAL TRANSPORT; CELL LINE; HUMANS; MEMBRANE TRANSPORT PROTEINS; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; SYMPORTERS; WAKEFULNESS;

EID: 77955662745     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.06.012     Document Type: Article

References (42)

1. Chang C., Ekins S., Bahadduri P., Swaan P.W. Pharmacophore-based discovery of ligands for drug transporters. Adv Drug Deliv Rev 2006, 58:1431-1450.
2. Metz J.T., Huth J.R., Hajduk P.J. Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups. J Comput Aided Mol Des 2007, 21:139-144.
3. Huth J.R., Song D., Mendoza R.R., Black-Schaefer C.L., Mack J.C., Dorwin S.A., et al. Toxicological evaluation of thiol-reactive compounds identified using a la assay to detect reactive molecules by nuclear magnetic resonance. Chem Res Toxicol 2007, 20:1752-1759.
4. Coan K.E., Shoichet B.K. Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. J Am Chem Soc 2008, 130:9606-9612.
5. Seidler J., McGovern S.L., Doman T.N., Shoichet B.K. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J Med Chem 2003, 46:4477-4486.
6. Zheng X., Ekins S., Raufman J.P., Polli J.E. Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol Pharm 2009, 6:1591-1603.
7. Diao L., Ekins S., Polli J.E. Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing. Pharm Res 2009, 26:1890-1900.
8. Chipperfield A.R., Whittam R. Ouabain binding to the sodium pump. Nature 1973, 242:62-63.
9. Wong M.H., Oelkers P., Dawson P.A. Identification of a mutation in the ileal sodium-dependent bile acid transporter gene that abolishes transport activity. J Biol Chem 1995, 270:27228-27234.
10. Weinman S.A., Carruth M.W., Dawson P.A. Bile acid uptake via the human apical sodium-bile acid cotransporter is electrogenic. J Biol Chem 1998, 273:34691-34695.
11. Tamai I., Ohashi R., Nezu J., Yabuuchi H., Oku A., Shimane M., et al. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 1998, 273:20378-20382.
12. Koepsell H., Lips K., Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007, 24:1227-1251.
13. Fairman W.A., Vandenberg R.J., Arriza J.L., Kavanaugh M.P., Amara S.G. An excitatory amino-acid transporter with properties of a ligand-gated chloride channel. Nature 1995, 375:599-603.
14. Bohmer C., Philippin M., Rajamanickam J., Mack A., Broer S., Palmada M., et al. Stimulation of the EAAT4 glutamate transporter by SGK protein kinase isoforms and PKB. Biochem Biophys Res Commun 2004, 324:1242-1248.
15. Baringhaus K.H., Matter H., Stengelin S., Kramer W. Substrate specificity of the ileal and the hepatic Na(+)/bile acid cotransporters of the rabbit II. A reliable 3D QSAR pharmacophore model for the ileal Na(+)/bile acid cotransporter. J Lipid Res 1999, 40:2158-2168.
16. Mennini T., Fumagalli E., Gobbi M., Fattorusso C., Catalanotti B., Campiani G. Substrate inhibitors and blockers of excitatory amino acid transporters in the treatment of neurodegeneration: critical considerations. Eur J Pharmacol 2003, 479:291-296.
17. Balakrishnan A., Sussman D.J., Polli J.E. Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT). Pharm Res 2005, 22:1269-1280.
18. Jackson M., Song W., Liu M.Y., Jin L., Dykes-Hoberg M., Lin C.I., et al. Modulation of the neuronal glutamate transporter EAAT4 by two interacting proteins. Nature 2001, 410:89-93.
19. Rais R., Gonzalez P.M., Zheng X., Wring S.A., Polli J.E. Method to screen substrates of apical sodium-dependent bile acid transporter. AAPS J 2008, 10:596-605.
20. Motohashi N., Kawase M., Satoh K., Sakagami H. Cytotoxic potential of phenothiazines. Curr Drug Targets 2006, 7:1055-1066.
21. Nordenberg J., Fenig E., Landau M., Weizman R., Weizman A. Effects of psychotropic drugs on cell proliferation and differentiation. Biochem Pharmacol 1999, 58:1229-1236.
22. Sakagami H., Takahashi H., Yoshida H., Yamamura M., Fukuchi K., Gomi K., et al. Induction of DNA fragmentation in human myelogenous leukaemic cell lines by phenothiazine-related compounds. Anticancer Res 1995, 15:2533-2540.
23. Zhelev Z., Ohba H., Bakalova R., Hadjimitova V., Ishikawa M., Shinohara Y., et al. Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes Phenothiazines and leukemia. Cancer Chemother Pharmacol 2004, 53:267-275.
24. Shin S.Y., Kim S.Y., Kim J.H., Min D.S., Ko J., Kang U.G., et al. Induction of early growth response-1 gene expression by calmodulin antagonist trifluoperazine through the activation of Elk-1 in human fibrosarcoma HT1080 cells. J Biol Chem 2001, 276:7797-7805.
25. Hadjimitova V., Bakalova R., Traykov T., Ohba H., Ribarov S. Effect of phenothiazines on protein kinase C- and calcium-dependent activation of peritoneal macrophages. Cell Biol Toxicol 2003, 19:3-12.
26. Eghbal M.A., Tafazoli S., Pennefather P., O'Brien P.J. Peroxidase catalysed formation of cytotoxic prooxidant phenothiazine free radicals at physiological pH. Chem Biol Interact 2004, 151:43-51.
27. Katoh M., Nakajima M., Yamazaki H., Yokoi T. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res 2000, 17:1189-1197.
28. Zhang Y., Gupta A., Wang H., Zhou L., Vethanayagam R.R., Unadkat J.D., et al. BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res 2005, 22:2023-2034.
29. Zhou X.F., Coburn R.A., Morris M.E. Effects of new 4-aryl-1,4-dihydropyridines and 4-arylpyridines on drug efflux mediated by multidrug resistance-associated protein 1. J Pharm Sci 2005, 94:2256-2265.
30. Shukla S., Robey R.W., Bates S.E., Ambudkar S.V. The calcium channel blockers 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry 2006, 45:8940-8951.
31. Li R.W., Tse C.M., Man R.Y., Vanhoutte P.M., Leung G.P. Inhibition of human equilibrative nucleoside transporters by dihydropyridine-type calcium channel antagonists. Eur J Pharmacol 2007, 568:75-82.
32. van Rhee A.M., Jiang J.L., Melman N., Olah M.E., Stiles G.L., Jacobson K.A. Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors. J Med Chem 1996, 39:2980-2989.
33. Maeda S., Matsuoka I., Iwamoto T., Kurose H., Kimura J. Down-regulation of Na+/Ca2+ exchanger by fluvastatin in rat cardiomyoblast H9c2 cells: involvement of RhoB in Na+/Ca2+ exchanger mRNA stability. Mol Pharmacol 2005, 68:414-420.
34. Ekins S., Johnston J.S., Bahadduri P., D'Souza V.M., Ray A., Chang C., et al. In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Pharm Res 2005, 22:512-517.
35. Takeda M., Noshiro R., Onozato M.L., Tojo A., Hasannejad H., Huang X.L., et al. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur J Pharmacol 2004, 483:133-138.
36. Goard C.A., Mather R.G., Vinepal B., Clendening J.W., Martirosyan A., Boutros P.C., Sharom F.J., Penn L.Z. Differential interactions between statins and P-glycoprotein: Implications for exploiting statins as anticancer agents. Int J Cancer 2010, 10.1002/ijc.25295.
37. Kobayashi M., Otsuka Y., Itagaki S., Hirano T., Iseki K. Inhibitory effects of statins on human monocarboxylate transporter 4. Int J Pharm 2006, 317:19-25.
38. Lash L.H., Putt D.A., Cai H. Drug metabolism enzyme expression and activity in primary cultures of human proximal tubular cells. Toxicology 2008, 244:56-65.
39. Eguchi Y., Shimizu S., Tsujimoto Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res 1997, 57:1835-1840.
40. Govindarajan R., Leung G.P., Zhou M., Tse C.M., Wang J., Unadkat J.D. Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol 2009, 296:G910-G922.
41. Thomas P., Smart T.G. HEK293 cell line: a vehicle for the expression of recombinant proteins. J Pharmacol Toxicol Methods 2005, 51:187-200.
42. Braun A., Hammerle S., Suda K., Rothen-Rutishauser B., Gunthert M., Kramer S.D., et al. Cell cultures as tools in biopharmacy. Eur J Pharm Sci 2000, 11(Suppl. 2):S51-S60.